NCT00614822View on ClinicalTrials.gov

Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

August 22, 2016

Study Completion Date

August 22, 2016

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Carboplatin, Pemetrexed and Bevacizumab

Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Christiana Care Health Services

OTHER

NCT00614822 - Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter